Original ContributionsE-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology☆,☆☆
Section snippets
Case selection
Tumors samples were derived from patients with clinically localized and advanced hormone-refractory prostate cancer. One hundred twenty-eight cases of clinically localized prostate cancer were identified from the University of Michigan Prostate Specialized Program in Research Excellence (SPORE) Tumor Bank. All patients were operated on between 1993 and 1998 for clinically localized prostate cancer as determined by preoperative prostate-specific antigen (PSA) level, digital rectal examination,
E-cadherin expression in clinically localized prostate carcinoma
For the current study, 128 clinically localized prostate tumors were used. Patient demographics are shown in Table 1.Age (yr), median (range) 59 (39-80) Serum PSA, median (range) 6.4 (0.5-43.3) DRE Negative 79 (62%) Positive 49 (38%) Gleason Scores 5-6 52 (41%) 7 69 (54%) 8-9 7 (5%) Extraprostatic extension Negative 95 (74%) Positive 33 (26%) Seminal vesicle invasion Negative 121 (95%) Positive 7 (5%) Surgical
Discussion
To our knowledge, this is the first study examining E-cadherin using high-density TMAs to examine a wide spectrum of well-characterized prostate cancers ranging from relatively low-grade clinically localized prostate tumors (Gleason score 5-6) to hormone-refractory metastatic prostate tumors. Statistical trends were identified for aberrant E-cadherin expression and higher Gleason score, positive surgical margin status, and PSA recurrence. These associations were only observed when the TMA data
Acknowledgements
The authors acknowledge the continued support of the SPORE Prostate Cancer Database by Sargum Manley, Martin Sanda, and John Wei and secretarial assistance by Sally Pilon and Kathy Kaminski.
References (40)
- et al.
E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway
J Biol Chem
(1999) - et al.
E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder
Hum Pathol
(1995) - et al.
Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: Characterization of the human E-cadherin gene promoter
Biochem Biophys Res Commun
(1994) - et al.
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens
Urology
(1999) - et al.
Co-ordinated changes in expression of cell adhesion molecules in prostate cancer
Eur J Cancer
(1997) - et al.
Truncation of the beta-catenin binding domain of E-cadherin precedes epithelial apoptosis during prostate and mammary involution
J Biol Chem
(2000) - et al.
Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression
Hum Pathol
(2000) - et al.
N-cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells
Am J Pathol
(1999) - et al.
Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas
Cancer Res
(1989) - et al.
Expression of immunoreactive E-cadherin adhesion molecules in human cancers
Am J Pathol
(1991)
Expression of E- and P-cadherin in gastric carcinomas
Cancer Res
E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration
Cancer Res
Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features
Am J Pathol
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis
Cancer Res
Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma
J Pathol
E-cadherin expression in renal cell cancer and its significance in metastasis and survival
Br J Cancer
Expression of E- and N-cadherin in renal cell carcinomas, in renal cell carcinoma cell lines in vitro and in their xenografts
Int J Cancer
Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer
J Cancer Res Clin Oncol
Changes in E-cadherin immunoreactivity in the adenoma-carcinoma sequence of the large bowel
Virchows Arch
Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome
Br J Cancer
Cited by (154)
Relationship between apical junction proteins, gene expression and cancer
2020, Biochimica et Biophysica Acta - BiomembranesClinical significance of epithelial-mesenchymal transition markers in prostate cancer
2017, Human PathologyCitation Excerpt :Aberrant E-cadherin expression has been previously demonstrated to increase in PCa compared to the nontumoral prostate [6,8]. In CLC, we observed, like others, that aberrant or loss of E-cadherin membrane staining is associated with higher Gleason score [5-8,12,13]. In contrast with our results, some authors also found that loss of E-cadherin was more frequent in pT3 compared to pT2, but the scoring was different from ours, which was based on the level of membranous immunoreactivity with a cut-off of 70% [5,8].
Tissue Microarrays: A High-Throughput Technology for Translational Research
2023, Microarrays & Microplates: Applications in Biomedical SciencesThe role of E-Cadherin expression in primary site of breast cancer
2022, Archives of Gynecology and ObstetricsIntegrins and Epithelial-Mesenchymal Cooperation in the Tumor Microenvironment of Muscle-Invasive Lethal Cancers
2022, Frontiers in Cell and Developmental Biology
- ☆
Supported by the Specialized Program in Research Excellence (SPORE) in Prostate Cancer, National Cancer Institute grant P50 CA69568.
- ☆☆
Address correspondence and reprint requests to Mark A. Rubin, MD, Department of Pathology and Section of Urology, University of Michigan, 1500 East Medical Center Dr, Room 2G332/Box 0054, Ann Arbor, MI 48109-0054.